Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Board Approves Spin-off Of Drug Discovery Company

This article was originally published in The Pink Sheet Daily

Executive Summary

Indian firm reports $1.2 billion in sales for the first nine months of 2007.

You may also be interested in...



Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb

Ranbaxy is looking for more strategic product acquisitions to build its branded division, firm tells “The Pink Sheet” DAILY.

Ranbaxy/GSK Partnership Yields First Drug Candidate

Ranbaxy will develop a respiratory disease candidate through proof of concept under an expanded discovery agreement inked with GSK in February.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel